IQV

Clinical research company IQVIA (NYSE: IQV) reported Q3 2026 results topping the market’s revenue expectations, with sales up 8% year on year to $4.43 billion.

IQVIA delivered an 8% year-over-year revenue increase in Q3, with results that outpaced Wall Street expectations and prompted a positive market reaction.

IQVIA Holdings slipped about 0.8% in the first trading session after its Q3 2026 release, a muted move for a stock that has quietly added roughly 9.7% over the past three months. The reaction looks modest next to what the company just put on the tape.

IQVIA (NYSE:IQV) reported third-quarter results that exceeded the high end of its guidance ranges, supported by accelerating organic growth in its Commercial Solutions and R&D Solutions businesses, higher clinical win rates and strong free cash flow.

Revenue hit $4.4 billion with 8% growth; net new bookings surged 15% year over year.

Moby summary of IQVIA Holdings Inc.'s Q3 2026 earnings call

IQV's Q3'26 earnings beat estimates as revenues rise 8% y/y, led by strong clinical demand, robust R&D bookings and improved execution, prompting a view hike.

Clinical research company IQVIA (NYSE: IQV) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 8% year on year to $4.43 billion.

(IQV) on Tuesday reported third-quarter profit of $350 million.On a per-share basis, the Durham, North Carolina-based company said it had net income of $2.

IQVIA (IQV) delivered earnings and revenue surprises of +3.09% and +1.44%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?